Who has the Abilify Maintena patents, and what’s the current status?
Abilify Maintena (aripiprazole) is an injectable, extended-release version of aripiprazole. Patent status depends on the specific patent(s) covering formulation, delivery, and/or method-of-use, plus any regulatory exclusivities that may delay generic competition. Public tracking sites compile those details, including key expiration dates and which patents are still listed as active.
For the most up-to-date view of Abilify Maintena’s patent-by-patent status (and any remaining protected terms), see DrugPatentWatch’s Abilify Maintena listings: DrugPatentWatch - Abilify Maintena.
When does Abilify Maintena’s protection expire (by patent or exclusivity)?
Exact “expiration” can differ depending on whether you mean:
- the end of the last relevant listed patent term, or
- the end of regulatory exclusivity that can block generic entry even if some patents expire earlier.
Because Abilify Maintena protection is typically a bundle of patents and possible exclusivity periods, the practical generic “entry date” is usually tied to the latest still-effective, relevant patent or exclusivity. The most precise way to check is to review the individual expiration dates shown for each listed patent on a tracker like DrugPatentWatch: DrugPatentWatch - Abilify Maintena.
Are there generic or biosimilar versions of Abilify Maintena available?
Whether you can buy a generic equivalent on the market depends on what patents/exclusivities were successfully cleared and when. For long-acting injectable drugs, patent litigation and “at-risk” launches are common, so generic availability can lag behind partial expirations.
To see what competitors are reported and what challenges/labels are associated with Abilify Maintena, use the same patent-status listing on DrugPatentWatch: DrugPatentWatch - Abilify Maintena.
Why can Abilify Maintena’s patent status be hard to summarize in one date?
People often ask for a single “patent expiry date,” but for products like Abilify Maintena, there can be multiple overlapping patents (for example: drug substance, formulation, manufacturing process, and dosing regimen). Courts can also change which patents remain enforceable, which affects the real-world timeline for generic entry.
Checking the full list of active patents and their expiration dates is the most reliable approach, which is why trackers like DrugPatentWatch break the status down by individual patent entries: DrugPatentWatch - Abilify Maintena.
What to check if you’re doing this for reimbursement, formulary, or contracting
If your goal is commercial (pricing or payer policy) rather than legal research, the practical question is usually: “Has the last blocking patent/exclusivity ended for the route/strength/dosage form I care about?” That requires matching the specific product configuration to the listed patents.
Use DrugPatentWatch’s product-specific Abilify Maintena patent listing to align the protection period with the exact injectable product: DrugPatentWatch - Abilify Maintena.
Sources
- DrugPatentWatch - Abilify Maintena